Sugi Predict

Sugi Predict / Compounds / SCHEMBL4095710

SCHEMBL4095710

SCHEMBL4095710

O=C(O)CCN1C(=O)c2ccc(CN(C(=O)Nc3ccc(OC(F)(F)F)cc3)c3ccc4nc(S)sc4c3)cc2C1=O

nearest known ligand 0.43

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ GCGR P47871 3/20 0.43
▸ GIPR P48546 2/20 0.43
▸ GLP1R P43220 1/20 0.43
▸ EPHX2 P34913 9/20 0.39
▸ MAPT P10636 1/20 0.39
▸ HPGD P15428 3/20 0.37
▸ NPC1 O15118 1/20 0.37
▸ NFKB1 P19838 1/20 0.37
▸ RAB9A P51151 1/20 0.37
▸ NFKB2 Q00653 1/20 0.37
▸ RELA Q04206 1/20 0.37
▸ SMN1; SMN2 Q16637 1/20 0.37
▸ KIT P10721 1/20 0.37
▸ FLT1 P17948 1/20 0.37
▸ KDR P35968 1/20 0.37
▸ KDM4E B2RXH2 3/20 0.37
▸ ALDH1A1 P00352 3/20 0.37
▸ RECQL P46063 1/20 0.37
▸ HSD17B10 Q99714 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4086528 0.86 ALDH1A1 (0.41) EPHX2HPGDNPC1NFKB1RAB9A
SCHEMBL7080572 0.85 GCGR (0.44) GCGRGIPRGLP1REPHX2KIT
SCHEMBL4081246 0.81 GCGR (0.67) GCGRGIPRGLP1R
SCHEMBL2663200 0.80 GCGR (0.43) GCGRGIPRGLP1RHPGDKIT
SCHEMBL2663180 0.80 GCGR (0.47) GCGRGIPRGLP1REPHX2SMN1; SMN2
SCHEMBL4095719 0.80 MAPT (0.40) MAPTHPGDNPC1NFKB1RAB9A
SCHEMBL2860184 0.73 MAPT (0.39) GCGRGIPRGLP1REPHX2MAPT
SCHEMBL2868215 0.73 EPHX2 (0.42) GCGRGIPRGLP1REPHX2MAPT
SCHEMBL7161880 0.72 GCGR (0.55) GCGRGIPRGLP1REPHX2
SCHEMBL2867706 0.71 EPHX2 (0.42) EPHX2MAPTNPC1RAB9AFLT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090143592-A1 Glucagon Antagonists/Inverse Agonists NOVO NORDISK A/S (DK) 2009-06-04 — — US disclosed
US-20090143592-A1 Glucagon Antagonists/Inverse Agonists NOVO NORDISK A/S (DK) 2009-06-04 — — US disclosed
US-20090143592-A1 Glucagon Antagonists/Inverse Agonists NOVO NORDISK A/S (DK) 2009-06-04 — — US disclosed
EP-1183229-B1 GLUCAGON ANTAGONISTS/INVERSE AGONISTS NOVO NORDISK AS (DK) 2005-10-26 — — EP disclosed
US-20050203108-A1 Glucagon antagonists/inverse agonists PFIZER INC 2005-09-15 — — US disclosed
US-6875760-B2 Glucagon antagonists/inverse agonists NOVO NORDISK A/S (DK) 2005-04-05 — — US disclosed
US-6503949-B1 Treating Type 2 diabetes, hyperglycemia, impaired glucose tolerance or obesity NORO NORDISK A/S (DK) 2003-01-07 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050203108-A1 Glucagon antagonists/inverse agonists GLP1R, GPR119, GCGR GCGR 3/4885GIPR 4/4885GLP1R 1/4885
US-20090143592-A1 Glucagon Antagonists/Inverse Agonists GLP1R, GPR119, GCGR GCGR 3/4885GIPR 4/4885GLP1R 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.